10-Q: CeriBell Reports Revenue Growth Amidst Net Losses

CeriBell, Inc. announced a 33% increase in total revenue for the second quarter of 2026, reaching $28.1 million, but reported a net loss of $19.3 million.

Summary

• CeriBell, Inc. reported a 33% year-over-year increase in total revenue for the three months ended June 30, 2026, reaching $28.1 million, and a 31% increase for the six months ended June 30, 2026, reaching $54.6 million.
• The company experienced a net loss of $19.3 million for the three months ended June 30, 2026, and $39.0 million for the six months ended June 30, 2026.
• Operating expenses increased significantly, with R&D up 39% and Sales & Marketing up 40% for the three-month period.
• The company had $129.3 million in cash, cash equivalents, and marketable securities as of June 30, 2026, which management believes is sufficient for at least the next 12 months.
• CeriBell is involved in patent infringement litigation against Natus Medical Incorporated, with an initial determination expected by November 19, 2026.
• The company entered into a new Credit Agreement on August 5, 2026, providing a $30 million term loan facility and a $20 million revolving facility, using proceeds to repay prior debt.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as cautiously negative due to continued net losses and significant operating expenses, despite revenue growth. The company's reliance on future financing and the ongoing patent litigation present considerable risks.

Positives

• Total revenue increased by 33% to $28.1 million for the three months ended June 30, 2026, compared to the prior year period.
• Product revenue grew by 33% to $21.2 million for the three months ended June 30, 2026.
• Subscription revenue increased by 30% to $6.9 million for the three months ended June 30, 2026.
• Gross profit increased by 39% to $25.9 million for the three months ended June 30, 2026, with a gross margin of 92%.
• Product gross margin improved to 91% for the three months ended June 30, 2026.
• The company secured a new Credit Agreement providing access to significant debt financing.
• FDA granted 510(k) clearance for the Delirium Monitor System in December 2025 and for new algorithms and next-generation hardware in June 2026.

Negatives

• The company reported a net loss of $19.3 million for the three months ended June 30, 2026, and $39.0 million for the six months ended June 30, 2026.
• Operating expenses increased substantially, with Sales and Marketing expenses rising 40% ($7.0 million) for the three-month period.
• General and Administrative expenses increased by 30% ($3.4 million) for the three-month period, partly due to legal costs.
• Interest and other income, net decreased by 46% for the three-month period due to lower cash and marketable securities balances.
• The company has an accumulated deficit of $259.4 million as of June 30, 2026.
• The company expects to continue incurring losses in the near term.

Risks

• The company has a limited operating history and has experienced rapid growth, which may strain resources and make it difficult to evaluate future prospects.
• The company has a history of net losses and expects to incur additional substantial losses in the foreseeable future.
• Failure to achieve substantial market acceptance and adoption of the Ceribell System could harm the business.
• The company operates in a highly competitive industry, facing established players like Natus and Nihon Kohden.
• Changes in trade policy, tariffs, and reliance on international manufacturing expose the company to foreign operational and trade risks.
• The company's success depends on its ability to innovate at the pace of its competitors and manage the risks associated with AI technologies.
• The company is subject to extensive government regulation and oversight in the United States, and failure to comply could harm its business.
• The company is involved in patent infringement litigation against Natus Medical Incorporated, which could result in significant costs and diversion of management attention.

Future Outlook

The company believes its existing cash and marketable securities are sufficient to fund operations for at least the next 12 months. However, it anticipates continued losses in the near term due to ongoing development, sales and marketing efforts, and the costs associated with being a public company. Future capital needs will depend on market acceptance, product development pace, and sales growth.

Management Comments

• We expect our research and development expenses to increase as we continue to improve and optimize our products, leverage our platform to expand indications, and develop products for use beyond the acute care setting.
• We expect our sales and marketing expenses to increase for the foreseeable future as we continue to increase the size of our sales organization and market penetration in the United States, expand indications, and potentially establish an international presence.
• We expect that our general and administrative expenses will increase in the foreseeable future as we increase our headcount to support the continued growth of our business.

Industry Context

StockSavvy.ai notes that CeriBell operates in the competitive medical technology sector, specifically focusing on neurological diagnostics. The company's growth in revenue, despite ongoing losses, aligns with the trend of increasing adoption of AI-powered diagnostic tools in healthcare. However, the significant increase in operating expenses, particularly in sales and marketing, indicates a strong push for market penetration against established competitors.

Legal Proceedings

• CeriBell filed patent infringement complaints against Natus Medical Incorporated and related subsidiaries with the U.S. International Trade Commission (USITC) and the U.S. District Court for the District of Delaware on July 7, 2025.
• The USITC instituted an investigation on August 6, 2025, and the District Court stayed the action pending the USITC investigation.
• Trial proceedings concluded as of June 12, 2026, with parties in post-trial briefing; an initial determination is expected by November 19, 2026.

Related Party Transactions

• The Company paid Dr. Parvizi, a Director and Co-Founder, for consulting services and expense reimbursement, recording these as general and administrative expenses. These expenses were $48,000 for each of the three-month periods and $97,000 for each of the six-month periods ended June 30, 2026 and 2025.

Stakeholder Impact

• Shareholders may experience continued dilution if the company needs to raise additional capital through equity financing.
• Customers (hospitals) may benefit from improved diagnostic capabilities for neurological conditions.
• Employees may face uncertainty due to the company's continued losses and focus on growth, but also opportunities with expansion.
• Suppliers may experience increased demand as the company scales its operations.

Next Steps

• Continue to drive adoption and utilization of the Ceribell System in the United States.
• Expand into new indications and potentially new application areas.
• Pursue additional regulatory clearances in Europe and other international markets.
• Continue to invest in research and development to enhance the Ceribell System and AI algorithms.
• Manage operating expenses and focus on achieving profitability.

Key Dates

Recommendation

CeriBell shows promising revenue growth and strong gross margins, indicating market traction for its innovative medical technology. However, the continued significant net losses, increasing operating expenses, and ongoing patent litigation present substantial risks. The company's ability to manage its cash burn and achieve profitability in the near future remains a key concern. While the new credit facility provides liquidity, the overall financial health and the outcome of legal proceedings warrant a cautious 'hold' stance until clearer signs of sustainable profitability emerge.

Keywords

EEG, medical technology, neurological conditions, seizure detection, delirium monitoring, acute care, AI algorithms, FDA clearance